BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Monday, September 28, 2026
📌TL;DR
AbbVie's etentamig posted a 74.0% response rate versus 45.7% for standard therapy, with median progression free survival not reached, in Phase 3 CERVINO data presented Friday at the IMS meeting in Glasgow.
The FDA approved four drugs Friday: Mirum and Incyte's Atebrioz for fibrodysplasia ossificans progressiva, Lilly's once weekly insulin Onswik, Merck and Eisai's Welireg plus Lenvima combination in kidney cancer, and Olumiant for adolescents with severe alopecia areata.
Novo Nordisk signed an up to €1.165 billion license with Sweden's Nanexa for monthly and quarterly injectable versions of up to five obesity and cardiometabolic programs, per Nanexa's release.
ADARx priced an upsized $446.3 million IPO at $17.00 and closed its first session at $19.35; Precision Neuroscience raised a $250 million Series D, Genentech paid Earendil Labs $55 million upfront in an up to $1.5 billion bispecific pact, and City Therapeutics filed to go public.
Travere named former Amicus chief Bradley Campbell CEO effective December 1, per Fierce Biotech.
EASD opens today in Milan with 44 Novo abstracts; Kodiak and Mirum both report Phase 3 topline results this morning.
⚡ Executive Takeaway
Here is the pattern in a weekend that looks like six unrelated stories. AbbVie's bispecific matched cell therapy depth without the cell therapy supply chain. Lilly's new insulin compresses 365 injections a year into 52. Novo just paid platform money, not molecule money, for a coating that could make it 12, or 4. The connection is arithmetic the industry rarely says out loud: the molecules are converging. Incretins, insulins, and now BCMA binders are approaching interchangeable efficacy, and when efficacy converges, competition moves to the layer where products still differ: how the drug reaches the patient, how often, and who gets paid along the way.
That is why a delivery platform commanded platform scale money this week while excellent molecules get licensed for less, and why the FDA's busiest approval day of the month was really two delivery stories and a label expansion. Our new through line for the week: watch the delivery layer. Every readout in Milan, the Wegovy pill's real world hold, the amylin dosing curves, CagriSema's composition data, is at bottom a question about format and interval. We grade it Friday.
🩸 Hematology
An off the shelf bispecific kept its median out of reach in a randomized myeloma trial, and the sequencing debate starts over. ABBV | JNJ | GILD
The CERVINO figures, presented Friday in Glasgow and reported by OncLive and Targeted Oncology: 74.0% response versus 45.7%, median progression free survival not reached versus 6.2 months, hazard ratio 0.40, in triple class exposed, anti BCMA naive patients after a median of three prior lines. Twelve month survival ran 87.9% versus 72.0% but has not crossed its formal boundary. The same meeting carried Carvykti's five year durability, half of CARTITUDE-2 Cohort A patients progression free at 60.7 months per BioSpace, and an indirect comparison favoring anito-cel ahead of its December 23 action date. ABBV closed the day essentially flat; the September 3 topline had already collected the market's reaction, and the field now argues over treatment slots, not assets.
💉 Diabetes and Obesity
The dosing interval race opened on two fronts in one day. LLY | NVO
The FDA approved Onswik (insulin efsitora alfa-gobe), Lilly's once weekly basal insulin, on QWINT program data from more than 3,400 patients, per Lilly's release, setting up a head to head with Novo's Awiqli and its five month launch head start. The same day Novo licensed Nanexa's PharmaShell platform for up to €1.165 billion, an atomic layer deposition particle coating aimed at monthly and quarterly versions of up to five cardiometabolic assets, per Nanexa's release. The two stories are one story: with weekly injectables converging on similar efficacy, interval is becoming the differentiator, and EASD opens today in Milan as the first dated test, with zenagamtide Phase 2b and the Wegovy pill's real world data both printing Wednesday.
🏛️ Regulatory
The FDA approved four drugs in one day, and finished building a two drug market for a disease that had no treatment five weeks ago. MIRM | INCY | MRK
Friday's slate: Atebrioz (zilurgisertib) for fibrodysplasia ossificans progressiva, Onswik, Welireg plus Lenvima in previously treated clear cell kidney cancer, and Olumiant extended to age 12 and up in severe alopecia areata, each per its sponsor's release or the FDA notice. The FOP approval is the one to sit with. A disease in which soft tissue turns to bone had no treatment until late August; it now has Regeneron's intravenous Activin A blocker and an oral ALK2 inhibitor that Mirum licensed from Incyte in April for $16 million upfront, per Fierce. The approval crossed at Friday's close, so Monday is MIRM's first reaction session, on a morning when the company also reports its hepatitis delta Phase 3 topline.
💰 Capital Markets
The IPO window paid up for quality and kept marking down the rest. ADRX | ETRA
ADARx priced an upsized $446.3 million IPO at $17.00, with AbbVie adding up to $100 million in a concurrent placement, and closed its first session at $19.35, 13.8% above the offer, our arithmetic; BioSpace calls it 2026's third largest biotech IPO. Around it: Precision Neuroscience raised a $250 million Series D for its 1,024 electrode cortical interface, Genentech paid Earendil Labs $55 million upfront against more than $1.5 billion for AI designed oncology bispecifics, and City Therapeutics filed. Electra meanwhile closed at a new low, 23.0% below its issue price. Capital is sorting, not flooding, and the sort favors staged, de risked assets over sector membership.
🤖 Medtech
Robotic surgery is going back into the chest, and the lab industry is rewriting its own price list. ISRG
Intuitive won a CE mark for da Vinci 5 in adult cardiac surgery, including coronary artery bypass, and will build training programs with European cardiac societies, per MedTech Dive; the system already carries nine US cardiac clearances. In Washington, laboratory groups are pressing Congress for PAMA payment reform ahead of CMS's November fee schedule finalization, per MedTech Dive, the same November in which Galleri's FDA decision is expected. The diagnostics category's product rules and payment rules are being written in the same window, which is exactly when categories get shaped.
🏭 Manufacturing
Pandemic preparedness is being redesigned to pay for itself between emergencies.
BioSpace's biomanufacturing feature is worth an operator's time: HIPRA's EU funded SPEEDCELL project completed its first year building a modular platform reusable across programs, CEPI is embedding platform technologies with regional manufacturers for faster outbreak response, and the EU's HERA issued a crisis procurement handbook this month. The recurring theme, per Just-Evotec Biologics, is capacity that stays economically viable between emergencies rather than surge capacity that rusts. With Section 232 tariffs extending to all importers Tuesday, where capacity lives and what it costs to keep warm is no longer a procurement detail.
📋 Quick Hits
Travere named Bradley Campbell, who led Amicus through its $4.8 billion sale to BioMarin, as CEO effective December 1, per Fierce Biotech; Eric Dube steps down.
Nektar prevailed in its rezpeg litigation against Lilly, per BioSpace.
Lepu Medical sued NewCo model pioneer Su Zhang and her firm CoDevCo in New York federal court, alleging she worked for a direct competitor while serving as Lepu's exclusive dealmaker for GLP-1 assets, per Fierce Biotech's report of the filing.
HUTCHMED began a global trial of HMPL-A830, its KRAS and EGFR targeting antibody conjugate, per a Sunday release; Lundbeck is moving its US headquarters to Boston, per Fierce Pharma; Roche proposed former Takeda CEO Christophe Weber for its board, per Endpoints.
This morning: Kodiak's DAYBREAK Phase 3 topline in wet AMD at 8:30 am Eastern, and Mirum's AZURE-1 hepatitis delta topline call. Neither outcome was public as of Sunday night; both get graded in Tuesday's edition.
Still absent Sunday night, scopes per our searches: pricing documents for Fayuvi, Isembyld, and Lyrfigtu. The Atebrioz price watch opens at its October launch.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The full CERVINO data table and the BCMA landscape scorecard after IMS, asset by asset
The four approval slate with mechanisms, labels, and primary sources
The Nanexa deal terms and the EASD readout schedule, date by date through Thursday
The movers table: five Friday closes that carry a story, including ADARx against its offer price
📋 The Week in Review
Monday: Grail's briefing documents posted with no major concerns and GRAL jumped 33.7%; Telix agreed to buy ITM for $1.65 billion upfront; Novo fell 8% on its strategy day.
Tuesday: the FDA's own questions put a 35.0% sensitivity number in front of the panel; Celldex sold off on a double Phase 3 win; Viking jumped 35.7% on oral maintenance data.
Wednesday: the panel swept all three votes, 10 to 0 on safety, 6 to 4 on effectiveness, 7 to 2 on benefit risk, with GRAL halted throughout; Roche's sefaxersen hit in IgA nephropathy; the FDA approved Lyrfigtu, the first novel cancer drug from a Korean company.
Thursday: GRAL settled up 15.4% at $125.21 in its first reaction session; Viking priced $500 million; Lilly signed InnoCare for up to $3.35 billion; Acadia missed by six thousandths of a p value.
Friday: the CERVINO medians came due at IMS and the etentamig median was not reached; the FDA approved four drugs in one day; Novo signed Nanexa; ADARx opened 13.8% above its offer. The gauntlet finished three for three on dated disclosures, and the one frame it broke, that a pre event rally prepays the outcome, was our own, printed as such.
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The slot war in myeloma after CERVINO: why the fight has moved from response rates to treatment sequence, and the December date that decides who fits where
💊 What Novo actually bought for €1.165 billion: the manufacturing arithmetic behind monthly dosing, and why the coating may be worth more than another molecule
📊 The diagnostics rulebook is being written twice this November, and the order of the two decisions matters more than either one alone
🎯 Plus the full catalyst calendar rebuilt for EASD week: the Milan schedule day by day, the tariff and Medicaid deadlines, and the Q4 decision queue
Gauntlet week finished three for three on dated disclosures, and the one frame it broke was ours, which we printed. This week the argument moves to the delivery layer, and Milan gets a daily vote on it through Friday. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →